Compare Abeona Therapeutics Inc (ABEO) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Tripadvisor Inc Common Stock — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Tripadvisor Inc Common Stock trades at $13.04 (market cap $1.66B). The key difference: Tripadvisor Inc Common Stock is far larger — about 4.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| ABEO | TRIP | |
|---|---|---|
Market Cap | $373.32M | $1.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $19.14 |
52-Week Low | $4.17 | $9.24 |
Enterprise Value | $228.22M | $1.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TRIP trades at $13.72, down 3.99% today, with a consensus price target of $13.87. The stock shows a bullish technical trend and recently announced the $700 million sale of TheFork to American Express. Despite mixed quarterly earnings, 2025 revenue grew to $1.89 billion with a net income margin of 0.99%. Analyst sentiment is mixed, with 60.72% holding and 23.21% recommending buy.
The outlook is cautiously optimistic. The sale of TheFork provides cash but removes a growth segment. Earnings volatility and competitive pressures in online travel pose risks. Upside depends on execution in core segments and macroeconomic stability. Current valuation metrics suggest the stock is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
